The endocannabinoid system (ECS), comprising the endogenous lipid mediators G-protein-coupled cannabinoid receptors in the skin, has been implicated in multiple regulatory functions and biological processes (e.g., proliferation, growth, differentiation, apoptosis and cytokine, mediator or hormone production of various cell types of the skin and appendages, such as the hair follicle and sebaceous gland).
The cutaneous ECS balance proliferation, differentiation and survival and the immune response of skin cells: It has been established that CBD directly interacts and binds to TRPV1 receptors, which have important roles in skin health and in certain skin disorders, especially in ones associated with inflammation, pain, itch and allergic contact dermatitis.
Study conducted in 2003 using transdermal application of ethosomal CBD prevented induced inflammation and edema induced in animal model and demonstrated the potential of transdermal CBD to be used as an anti-inflammatory treatment. In conclusion, animal studies showed potential of CBD and cannabinoids of activating TRPV1 pathway, which can reduce inflammation and allergic response.
Furthermore, TRPV1 pathway and CBD as its agonist have been shown to be have analgesic effects properties in both humans and animals by activation of CB1 and/or CB2 and TRPV1) at sensory nerve terminals and/or inflammatory cells.
Petrosino, Stefania, et al. “Anti-inflammatory properties of cannabidiol, a nonpsychotropic cannabinoid, in experimental allergic contact dermatitis.” Journal of Pharmacology and Experimental Therapeutics 365.3 (2018): 652-663.
Re, Giovanni, et al. “Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals.” The Veterinary Journal 173.1 (2007): 21-30.